Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2008

01.12.2008 | Hepatic and Pancreatic Tumors

Tumour Size and Differentiation in Predicting Recurrence of Hepatocellular Carcinoma After Liver Transplantation: External Validation of a New Prognostic Score

verfasst von: L. Marelli, MD, A. Grasso, MD, M. Pleguezuelo, MD, H. Martines, MD, R. Stigliano, MD, A. P. Dhillon, FRCP, FRCPath, D. Patch, FRCP, B. R. Davidson, FRCS, D. Sharma, FRCS, K. Rolles, FRCS, A. K. Burroughs, MB, ChB (Hons), FRCP

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

A new prognostic score including tumour differentiation—establishing two groups of patients: group A with >3 points and group B with >4 points—improved the accuracy of the Milan criteria in predicting recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) in a large multicentre study (Decaens 2007).

Aim

The aim of this study was to validate the new score in our HCC cohort.

Methods

The study involved 100 consecutive patients with mean age 55 years (range 31–68 years) (M/F: 88/22) transplanted for known HCC: 60 unifocal and 40 multifocal (2–3 nodules in 32 and ≥4 nodules in 8) at pre-LT imaging. Survival differences were analysed by log-rank test. Patient/tumour variables before LT and tumour differentiation at explant were assessed by univariate/multivariate analysis.

Results

Median follow-up was 29 months (range 1–145 months). HCC recurrence was recorded in 18 patients. Five-year recurrence-free survival rate was 67 ± 7%. Patient survival at 3 months was 84 ± 4% and at 5 years was 45 ± 6%. Both recurrence-free survival and patient survival were not significantly different between groups A and B. Diameter of largest nodule was the sole pre-LT variable independently associated with recurrence [odd ratio (OR) 1.07; 95% confidence interval (CI) 1.01–1.12; P = 0.012]. Recurrence-free survival was significantly better in patients with diameter <30 mm compared with those with larger nodules (P = 0.0229). Number of nodules and tumour differentiation did not influence recurrence. There were three HCC recurrences with largest nodule size <30 mm, seven recurrences between 30–40 mm, and eight recurrences >40 mm.

Conclusion

Tumour differentiation did not add significantly to prediction of HCC recurrence in our cohort. Conversely, diameter of the largest nodule remained a significant risk for recurrence.
Literatur
1.
Zurück zum Zitat Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003;60:145–50PubMedCrossRef Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003;60:145–50PubMedCrossRef
2.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9PubMedCrossRef Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9PubMedCrossRef
3.
Zurück zum Zitat Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403PubMedCrossRef Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403PubMedCrossRef
4.
Zurück zum Zitat Mejia GA, Gomez MA, Serrano J, et al. Correlation between the radiologic and histologic size of hepatocellular carcinoma in patients eligible for liver transplantation. Transplant Proc 2006;38:1394–5PubMedCrossRef Mejia GA, Gomez MA, Serrano J, et al. Correlation between the radiologic and histologic size of hepatocellular carcinoma in patients eligible for liver transplantation. Transplant Proc 2006;38:1394–5PubMedCrossRef
5.
Zurück zum Zitat Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006;81:1633–9PubMedCrossRef Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006;81:1633–9PubMedCrossRef
6.
Zurück zum Zitat Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587–96PubMedCrossRef Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587–96PubMedCrossRef
7.
Zurück zum Zitat Benckert C, Jonas S, Thelen A, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters. Transplant Proc 2005;37:1693–4PubMedCrossRef Benckert C, Jonas S, Thelen A, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters. Transplant Proc 2005;37:1693–4PubMedCrossRef
8.
Zurück zum Zitat Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–38PubMedCrossRef Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–38PubMedCrossRef
9.
Zurück zum Zitat Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007;13:543–51PubMedCrossRef Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007;13:543–51PubMedCrossRef
10.
Zurück zum Zitat Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086–92PubMedCrossRef Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086–92PubMedCrossRef
11.
Zurück zum Zitat Ramos E, Llado L, Serrano T, et al. Utility of cell-cycle modulators to predict vascular invasion and recurrence after surgical treatment of hepatocellular carcinoma. Transplantation 2006;82:753–8PubMedCrossRef Ramos E, Llado L, Serrano T, et al. Utility of cell-cycle modulators to predict vascular invasion and recurrence after surgical treatment of hepatocellular carcinoma. Transplantation 2006;82:753–8PubMedCrossRef
12.
Zurück zum Zitat Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603–8PubMedCrossRef Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603–8PubMedCrossRef
13.
Zurück zum Zitat Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708–16PubMedCrossRef Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708–16PubMedCrossRef
14.
Zurück zum Zitat Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002;6:224–32PubMedCrossRef Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002;6:224–32PubMedCrossRef
15.
Zurück zum Zitat Lohe F, Angele MK, Gerbes AL, et al. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005;31:994–9PubMedCrossRef Lohe F, Angele MK, Gerbes AL, et al. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005;31:994–9PubMedCrossRef
16.
Zurück zum Zitat Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004;10:1195–202PubMedCrossRef Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004;10:1195–202PubMedCrossRef
17.
Zurück zum Zitat Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136:25–30PubMedCrossRef Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136:25–30PubMedCrossRef
18.
Zurück zum Zitat Grasso A, Stigliano R, Morisco F, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 2006;81:1532–41PubMedCrossRef Grasso A, Stigliano R, Morisco F, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 2006;81:1532–41PubMedCrossRef
19.
Zurück zum Zitat Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150–9PubMedCrossRef Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150–9PubMedCrossRef
20.
Zurück zum Zitat Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080–6PubMedCrossRef Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080–6PubMedCrossRef
21.
Zurück zum Zitat Sutcliffe R, Maguire D, Portmann B, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 2006;93:11–8PubMedCrossRef Sutcliffe R, Maguire D, Portmann B, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 2006;93:11–8PubMedCrossRef
22.
Zurück zum Zitat Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol 2003;21:4265–7PubMedCrossRef Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol 2003;21:4265–7PubMedCrossRef
23.
Zurück zum Zitat Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437–47PubMedCrossRef Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437–47PubMedCrossRef
24.
Zurück zum Zitat Decaens T, Roudot-Thoraval F, Badran H, et al. Liver tansplantation for hepatocellular carcinoma: validation of a new prognostic score predicting disease-free survival. J Hepatol 2007;46:S25. Ref Type: Abstract Decaens T, Roudot-Thoraval F, Badran H, et al. Liver tansplantation for hepatocellular carcinoma: validation of a new prognostic score predicting disease-free survival. J Hepatol 2007;46:S25. Ref Type: Abstract
25.
Zurück zum Zitat Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef
26.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–30PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–30PubMedCrossRef
27.
Zurück zum Zitat Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006;12:1761–9PubMedCrossRef Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006;12:1761–9PubMedCrossRef
28.
Zurück zum Zitat An FQ, Matsuda M, Fujii H, et al. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of P53 and beta-catenin. Int J Cancer 2001;93:468–74PubMedCrossRef An FQ, Matsuda M, Fujii H, et al. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of P53 and beta-catenin. Int J Cancer 2001;93:468–74PubMedCrossRef
29.
Zurück zum Zitat Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 2007;245:435–42PubMedCrossRef Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 2007;245:435–42PubMedCrossRef
30.
Zurück zum Zitat Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma—Yes, of course! J Hepatol 2005;43:569–73PubMedCrossRef Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma—Yes, of course! J Hepatol 2005;43:569–73PubMedCrossRef
31.
Zurück zum Zitat Zimmerman MA, Trotter JF, Wachs M, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int 2007;20:747–53PubMedCrossRef Zimmerman MA, Trotter JF, Wachs M, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int 2007;20:747–53PubMedCrossRef
32.
Zurück zum Zitat Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911–8PubMedCrossRef Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911–8PubMedCrossRef
33.
Zurück zum Zitat Tanaka H, Kubo S, Tsukamoto T, et al. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 2005;37:1254–6PubMedCrossRef Tanaka H, Kubo S, Tsukamoto T, et al. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 2005;37:1254–6PubMedCrossRef
34.
Zurück zum Zitat Yao FY. Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number? Liver Transpl 2006;12:1189–91PubMedCrossRef Yao FY. Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number? Liver Transpl 2006;12:1189–91PubMedCrossRef
35.
Zurück zum Zitat Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260–7PubMedCrossRef Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260–7PubMedCrossRef
36.
Zurück zum Zitat Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?—No, never. J Hepatol 2005;43:573–7PubMedCrossRef Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?—No, never. J Hepatol 2005;43:573–7PubMedCrossRef
Metadaten
Titel
Tumour Size and Differentiation in Predicting Recurrence of Hepatocellular Carcinoma After Liver Transplantation: External Validation of a New Prognostic Score
verfasst von
L. Marelli, MD
A. Grasso, MD
M. Pleguezuelo, MD
H. Martines, MD
R. Stigliano, MD
A. P. Dhillon, FRCP, FRCPath
D. Patch, FRCP
B. R. Davidson, FRCS
D. Sharma, FRCS
K. Rolles, FRCS
A. K. Burroughs, MB, ChB (Hons), FRCP
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0128-3

Weitere Artikel der Ausgabe 12/2008

Annals of Surgical Oncology 12/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.